Scinai Immunotherapeutics
SCNI
2 hedge funds and large institutions have $126K invested in Scinai Immunotherapeutics in 2015 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
29% less capital invested
Capital invested by funds: $177K → $126K (-$51K)
60% less funds holding
Funds holding: 5 → 2 (-3)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$46K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$13K |
| 3 |
Citigroup
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VIA
1
Vantage Investment Advisors
State College,
Pennsylvania
| $67K | – | – | – |
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $59K | – | – | – |
|
|
3
Jane Street
New York
| – | -$46K | -124 | Closed |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$13K | -35 | Closed |
|
|
5
Citigroup
New York
| – | -$1K | -3 | Closed |
|
SCNI Hedge Fund Activity: Q4 2015 in Review
2 of the 3,813 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2015, worth a combined $126K — down 29% from $177K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Jane Street, exiting entirely with an estimated $46K sold.
- 2 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2015, down from 5 in Q3 2015.
- Funds reported $126K of Scinai Immunotherapeutics stock for Q4 2015, down 29% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q4 2015 and 3 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics seller in Q4 2015 was Jane Street, an estimated $46K sold.
Based on aggregated 13F filings for Q4 2015.